![](https://investorshub.advfn.com/uicon/413007.png?cb=1673699831)
Saturday, August 04, 2018 3:05:19 PM
There are not many CEO's that have taken a company from development stage into commercialization much less ones that kept the financial fundamentals of the company strong while maintaining minimum shareholder dilution. Comments and attacks about Dr. Chan seem to come out of the woodwork whenever there is an unexpected hit to the share price. I for one am glad that the management team remains focused on their strategy and is executing on it, albeit at what appears on the surface at the expense of 'exponential growth'.
I was traveling this past week and not able to listen to the conference call but in reading through the transcript today, there were so many great nuggets of information that they seemed to have gotten overlooked due to the drop in the stock price, including:
• Very well capitalized, with a healthy cash balance of $25.3 million (sufficient to fund operations and clinical needs into 2020)
• Expansion of the inclusion criteria for REFRESH II which should improve operational aspects of the patient screening process enhance (accelerate) the rate of enrollment
• Record sales quarter with annualized product sale run rate of approximately $21 million, as compared to approximately $12.2 million just 1 year ago
• Management (normally very conservative) is "very optimistic" about continuing sales growth, particularly with regard to the second half of 2018. (read into this what you will)
• Narrowed operating loss as defined to approximately $300,000 and very close to operating breakeven
• Sales are developing into "more of a pull market versus a push market" and seeing a lot of activity, a lot of interest from clinicians, not just in Germany but in other parts of the world (this point is important as reorders are not only accelerating but increasing, mostly due to clinical and real world evidence the device works)
• Blended gross margin of 74% based on old manufacturing facility, and is expecting to improved in Q3, then again in Q4 and into 2019 (Medtronic has one of the highest gross margins in the medical device space of 68% as of their latest quarter, compared to an industry average of 59%)
• Completed all the tooling for the Hemodefend project and have begun to do essentially the validation product builds. With those validation builds will start the clinical build for the product, which will be done later this year. (from what I have read in the past they can also start commercial manufacturing for Hemodefend in the new plant and if they are able to sign a licensing or distribution partnership they can always outsource the manufacturing of this product)
• Able to double manufacturing capacity to support a $80 million thresshold with less than a $100,000 additional capital investment (how many other companies have you seen build and get ISO-certified a brand new manufacturing plant and can do this?).
While sales growth is important, a lot of investors neglect to see what is happening on the cost side of things. Operating profitability is just as important to the management team and thus you have seen them be very strategic and excel at managing the growth and incurring cost only in areas where there is a direct benefit to that aspect of the business. This will ultimately make the company even more valuable. I posted a little about this "balanced growth approach" here: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141425194
"Now, our interim target is to get the operating profitability. We think that that will be an important inflection point for our business, and we will significantly cut down on the cash needs of the Company, but also make our company much more attractive to a wide variety of different interested groups."
Recent CTSO News
- CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/26/2024 09:14:03 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/26/2024 09:11:21 PM
- CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress • GlobeNewswire Inc. • 07/17/2024 11:00:00 AM
- CytoSorbents Secures $20 Million Credit Facility • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:31:20 PM
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:14:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:00:30 PM
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM